GlobeNewswire Inc | Jul 21, 2020 05:00PM EDT

July 21, 2020

SOUTH SAN FRANCISCO, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Alector, Inc.(Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the company will highlight preliminary data from a Phase 2 open-label study evaluating AL001 in individuals with frontotemporal dementia at the upcoming 2020 Alzheimers Association International Conference being held virtually, July 27-31, 2020.

Details for the oral presentation:

Presentation Title: AL001 Restores CSF PGRN Levels and Normalizes Disease-associated Biomarkers in Individuals with Frontotemporal Dementia due to Heterozygous Mutations in the Progranulin Gene

Session Name: Human: Putative Therapeutic Results for Alzheimers and Related DementiasPresenter: Robert Paul, M.D., Ph.D., Chief Medical Officer, AlectorDate:Presentation will be available on-demand beginning Tuesday, July 28, 2020 at 6 p.m. Eastern Time

AboutAlectorAlectoris a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders.Alectoris developing a broad portfolio of programs designed to functionally repair genetic mutations that cause dysfunction of the brains immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. The Companys product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimers disease.Alectoris headquartered inSouthSan Francisco, California. For additional information, please visit www.alector.com.

Source: Alector, Inc.

Contacts

Media: 1AB Dan Budwick, 973-271-6085dan@1abmedia.com

or

Investors: Alector, Inc.ir@alector.com